PURPOSE: Sarcoidosis is a multisystemic disease that is most common present in lungs, but in a great amount of patients it is possible to detect its presence in other organs.
METHODS: In the cross-sectional study in 81 biopsy proven sarcoidosis patients (20 males) with average disease duration of 14 ± 8 years (mean FEV1 was 107 ± 19% predicted), we compared the severity of fatigue and dyspnea symptoms and health status scores between patients with pulmonary and extrapulmonary sarcoidosis. Fatigue was assessed by the standardized Fatigue Scale, which contains 14 items, with four response options (the higher the score, the more severe fatigue). Scale distinguishes mental fatigue, describing cognitive difficulties, physical fatigue, and it is also possible to calculate a total fatigue score. Dyspnea was determined by the Baseline Dyspnea Index (BDI), Modified Medical Research Council Dyspnea Scale (MRC), and the List of Daily Activities (DAL). Health status was measured by the St George s Respiratory Questionnaire (SGRQ), and its total as well as scores for individual domains (symptoms, activity and impacts), were calculated for each patient. Patients did not have any associated ilnesses that could influence their health status.
RESULTS: By means of T-Test for independent samples, statistically significant difference between the average of all symptoms (except of MRC) and total and activity domain SGRQ scores with regard to the patient groups was established. The highest difference was found for BDI mean scores, and SGRQ activity domain score (t = - 4.5; p < 0.001, and t = 2.6; p = 0.010, respectively).
CONCLUSION: There are big differences in the severity of symptoms and the health status impairment between the patients with pulmonary and extrapulmonary sarcoidosis. They are bigger in patients with pulmonary sarcoidosis.
CLINICAL IMPLICATIONS: All applied instruments have good measurement properties both for research purposes and practical work with sarcoidosis patients.
DISCLOSURE: Branislav Gvozdenovic, No Financial Disclosure Information; No Product/Research Disclosure Information